J&J is the third medtech company to gain U.S. approval for pulsed field ablation, a new atrial fibrillation treatment seeing rapid adoption.

CEO Bernd Montag said the company is well positioned for a “U.S. versus China situation” that could arise when Donald Trump ...

The Aventus thrombectomy system uses technology that tells the operator if the device’s tip is in contact with blood, a clot ...

SYNDEO Medical, a Belgium-based leader in diagnostic and interventional procedural solutions, announces that its two flagship product brands, SYNDEOPack Interventional Procedure Packs™ and Xssential ...

Executives said the patient monitoring company’s consumer business will likely become a discontinued operation if it is not ...

CEO Eric Lefkofsky said the purchase of Ambry Genetics will expand Tempus’ testing portfolio and bring in a fast-growing ...

Baxter will share an update on Hurricane Helene’s impact, while Medtronic will likely discuss a new pulsed field ablation ...

Integra Lifesciences appointed former 3M executive Mojdeh Poul as CEO. Poul will take over from Jan De Witte in January, ...

Roots Community Health has sued 12 other firms, including GE Healthcare, CVS and Walgreens, and called for manufacturers and ...

Cortex adds to Boston Scientific’s electrophysiology portfolio amid treatment shifts in the space driven by new pulsed field ...

NeuroOne will get $3 million upfront for an exclusive license to distribute its radiofrequency ablation system designed to treat neurological disorders such as epilepsy and Parkinson's disease.

The LHM platform integrates seamlessly with Echosens’ FibroScan® technology, offering automated result transfers, biological marker-enhanced exams, and interpretation tools that support more informed, ...